jcm-logo

Journal Browser

Journal Browser

Drug-Related Problems: Clinical Pharmacy and Safety of Pharmacotherapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 15 February 2026 | Viewed by 1013

Special Issue Editors


E-Mail Website
Guest Editor
Department of Humanities and Social Medicine, Medical University of Lublin, Lublin, Poland
Interests: pharmaceutical care; clinical pharmacy; pharmacology; pharmacoeconomic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue aims to highlight pharmacotherapeutic safety. Drug problems such as adverse drug reactions, drug interactions, or pharmacotherapy errors and the possibility of preventing them, detecting them, and examining recent advances in understanding their occurrence are now a challenge for medicine to ensure patient safety.

This Special Issue aims to cover the field of clinical pharmacy services as a tool for ensuring safety in pharmacotherapy.

Drug problems such as adverse drug reactions, drug interactions, dosage errors, or medication administration errors cause many clinical but also economic consequences for the patient as well as the health care system. Many of these drug problems also have ethical implications for medical personnel in particular.

Studies using clinical trials, observational studies, and advanced analytical methods to improve the safety of pharmacotherapy are welcome.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: drug-related problems, clinical pharmacy, clinical pharmacology, pharmaceutical care, pharmacotherapy, adverse drug reactions, drug interactions, and ethics in scientific research.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Medicines.

Dr. Mariola Drozd
Prof. Dr. Jakub Pawlikowski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adverse drug reaction
  • drug-related problems
  • drug formulation technology
  • safety of pharmacotherapy
  • clinical pharmacy
  • pharmaceutical care
  • pharmacology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 759 KB  
Review
Prevalence of Polypharmacy Among Patients with Chronic Liver Disease—A Narrative Literature Review
by Monika Szkultecka-Dębek, Lucyna Bułaś, Agnieszka Skowron and Mariola Drozd
J. Clin. Med. 2025, 14(17), 6263; https://doi.org/10.3390/jcm14176263 - 5 Sep 2025
Viewed by 852
Abstract
Background and aim: Managing the therapy of patients with chronic liver diseases and comorbidities presents significant challenges for physicians and pharmacists, particularly regarding drug-induced liver damage and polypharmacy. Given the liver’s central role in drug detoxification, polypharmacy in liver disease requires special attention. [...] Read more.
Background and aim: Managing the therapy of patients with chronic liver diseases and comorbidities presents significant challenges for physicians and pharmacists, particularly regarding drug-induced liver damage and polypharmacy. Given the liver’s central role in drug detoxification, polypharmacy in liver disease requires special attention. The aim of the review was to assess the prevalence of polypharmacy among patients with chronic liver diseases. Approach and Results: A literature search focused on randomized controlled trials, database reviews, and medical records. Review of PubMed, SCOPUS, and ScienceDirect databases identified 2578 manuscripts, however only 11 studies met the inclusion criteria. The results of studies showed that the prevalence of polypharmacy among patients with chronic liver disease can exceed 50%, and can lead to high prevalence of MRP and pDDI among those patients. Conclusions: Findings reveal a critical link between polypharmacy and adverse outcomes in chronic liver diseases, including cirrhosis, hepatitis, and non-alcoholic fatty liver disease. Individualized treatment plans, considering factors such as age, gender, comorbidities, and liver disease severity are essential. The interventions focused on mitigating MRP and reducing pDDI need to be implemented in order to reduce the potential harm of polypharmacy. Full article
Show Figures

Figure 1

Back to TopTop